| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases (NCT05026983) | M.D. Anderson Cancer Center | 2021-12-27 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (NCT05039801) | M.D. Anderson Cancer Center | 2021-09-30 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (NCT04940299) | M.D. Anderson Cancer Center | 2021-09-23 |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma (NCT04527549) | ECOG-ACRIN Cancer Research Group | 2021-06-01 |
| Bone Loss in Melanoma Survivors Receiving Immunotherapy (NCT04516122) | M.D. Anderson Cancer Center | 2021-05-10 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040) | M.D. Anderson Cancer Center | 2021-04-14 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (NCT03819296) | M.D. Anderson Cancer Center | 2021-02-21 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (NCT04752267) | University of Southern California | 2021-02-15 |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial (NCT04462406) | ECOG-ACRIN Cancer Research Group | 2021-02-09 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases (NCT04511013) | SWOG Cancer Research Network | 2021-01-06 |
| Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma (NCT04375527) | Jonsson Comprehensive Cancer Center | 2020-12-03 |
| The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients (NCT05102773) | Ohio State University Comprehensive Cancer Center | 2020-02-10 |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (NCT03816332) | National Cancer Institute (NCI) | 2019-11-08 |
| CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma (NCT03727789) | Roswell Park Cancer Institute | 2019-07-01 |
| Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain (NCT03873818) | M.D. Anderson Cancer Center | 2019-02-21 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |
| Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases (NCT03175432) | M.D. Anderson Cancer Center | 2017-06-15 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Ipilimumab and Imatinib Mesylate in Advanced Cancer (NCT01738139) | M.D. Anderson Cancer Center | 2013-02-19 |
| Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases (NCT01644591) | M.D. Anderson Cancer Center | 2012-08-02 |